Compare Amgen, Inc. (AMGN) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Kaltura Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Kaltura Inc trades at $1.26 (market cap $191.73M). The key difference: Amgen, Inc. is far larger — about 1022.9× Kaltura Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| AMGN | KLTR | |
|---|---|---|
Market Cap | $196.12B | $191.73M |
Sector | Health | Technology |
52-Week High | $388.16 | $1.97 |
52-Week Low | $271.18 | $1.08 |
Enterprise Value | $241.41B | $174.45M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Kaltura (KLTR) trades at $1.28, up 0.79% with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent industry recognitions highlight Kaltura's leadership in AI-powered digital engagement platforms, though negative ROE and high P/B ratio of 41.29 indicate valuation concerns.
While Kaltura demonstrates operational improvement and strong industry positioning, the stock faces headwinds from persistent losses and bearish technical signals. The mixed analyst sentiment (44% buy, 33% hold, 22% sell) reflects uncertainty about profitability timeline. Investment appeal hinges on the company's ability to convert AI innovation into sustainable earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
